血塞通联合前列地尔治疗脑梗塞的临床效果

摘要

Objective To explore the effect of Xuesaitong combined with alprostadil in the treatment of cerebral infarction. Methods Convenient selection 106 cases of patients with cerebral infarction treated in our hospital from December 2015 to August 2016 were included, were randomly assigned for control group (50 cases) and observation group (56 cases), treated with alprostadil treatment and Xuesaitong combined with prostaglandin PGE1 in the treatment. Results The observation group and control group of nerve function defect score (13.25±3.25) points and (12.15 ±4.29) points before treatment, the dif-ference was not statistically significant (P>0.05) respectively, after treatment, the scores of two groups compared with the group before treatment were significantly decreased and after treatment, observation group of nerve function defect score for (5.10 ±2.12)points was significantly lower than that of the control group for (6.85 ±2.35)points, (P< 0.05);The total effective rate of the observation group was 96.43%, significantly higher than 84% of the control group (P<0.05);There were no obvi-ous adverse reactions in the course of the treatment of the two groups. Conclusion Xuesaitong combined with prostaglandin PGE1 in the treatment of cerebral infarction can obtain satisfactory clinical results, and no significant adverse reactions, is a safe and effective treatment.%目的：探讨血塞通联合前列地尔治疗脑梗塞的临床效果。方法方便选取该院2015年12月-2016年8月收治的106例脑梗塞患者，随机分为对照组(50例)和观察组(56例)，分别给予前列地尔治疗和血塞通联合前列地尔治疗。结果观察组和对照组治疗前的神经功能缺损评分分别为(13.25±3.25)分和(12.15±4.29)分，经比较差异无统计学意义(P>0.05)，治疗后两组评分较之该组治疗前均显著下降，且治疗后观察组的神经功能缺损评分为(5.10±2.12)分显著低于对照组的为(6.85±2.35)分(P<0.05)；观察组的治疗总有效率为96.43%，显著高于对照组的84.00%(P<0.05)；两组患者治疗过程中均未出现明显的不良反应。结论血塞通联合前列地尔治疗脑梗塞可以获得理想的临床效果，且无明显不良反应，是一种安全有效的治疗方案。